A study in JAMA Oncology reveals that MyProstateScore 2.0, a new urine test analyzing 18 genes, surpasses PSA in detecting significant prostate cancers and could reduce unnecessary biopsies by up to 42%.
A new urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published on April 18 in JAMA Oncology. The urine test, MyProstateScore 2.0 (MPS2), was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection of worrisome prostate cancers, the researchers concluded.
"In nearly 800 patients with an elevated PSA level, the new test was capable of ruling out the presence of clinically significant prostate cancer with remarkable accuracy. This allows patients to avoid more burdensome and invasive tests, like MRI and prostate biopsy, with great confidence that we are not missing something," said Jeffrey Tosoian, MD, assistant professor of Urology and director of Translational Cancer Research at Vanderbilt University Medical Center, who is first author of the study.
Jeffrey Tosoian, MD, assistant professor of Urology and director of Translational Cancer Research at Vanderbilt University Medical Center, who is first author of the study.
Credit: Vanderbilt University Medical Center
Background on Prostate Cancer Screening
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the U.S. The PSA blood test has been widely used as the initial step in prostate cancer screening. Although PSA is elevated in the vast majority of men with prostate cancer, it is also elevated in a significant proportion of men without cancer.
As a result, the use of elevated PSA alone to prompt a prostate biopsy results in numerous unnecessary biopsies. Although generally safe, prostate biopsies are invasive, uncomfortable, and carry some risk of worrisome complications. Therefore, for patients with an elevated PSA, there is a great need for a second-line test to better identify which men truly need a biopsy and which do not.
Development of MPS2
Because some low-grade, prostate cancers do not require treatment and can be safely monitored with an approach termed active surveillance, the MPS2 test was developed to detect more specifically the higher-grade, "clinically significant" cancers in need of early detection and treatment.
To do this, the research team analyzed prostate tumors from across the U.S. to identify novel genes more often detected in the presence of significant cancers. The most informative 18 genes were combined into the MPS2 test, which was then tested in a National Cancer Institute trial of men with an elevated PSA level.
Uniquely, the authors were able to compare the novel test to other prostate cancer tests, including the original, two-gene MPS test.
Study Results and Comparison
The study involved 743 men with a median age of 62 years and a median PSA level of 5.6. While existing biomarker tests could have avoided 15% to 30% of unnecessary biopsies (i.e. biopsies that were negative or found low-grade cancers not requiring treatment), use of MPS2 would have avoided 35% to 42% of unnecessary biopsies without missing any additional diagnoses of clinically significant cancer.
The improvement was even more pronounced in men with a history of a previous negative biopsy, reducing the rate of unnecessary biopsies from 46% to 51% with use of MPS2, as compared to 9% to 21% for existing tests.
Future Research and Limitations
Multiparametric magnetic resonance imaging (mpMRI) is another second-line test that has been utilized, but while it can improve detection of clinically significant prostate cancer, interpretation of the results can be subjective and vary significantly. The authors also noted that mpMRI is not available in some community settings and is not an option for some patients. The current study was not designed to compare biomarkers to mpMRI, but the researchers are currently conducting a prospective, multicenter trial for that purpose.
In patients shown to be without clinically significant prostate cancer by the new test, the authors concluded that the "externally validated performance of MPS2 supports its effectiveness in accurately ruling out the need for mpMRI and biopsy altogether." They noted a limitation of the study was that only 13% of participants were African American. Because prostate cancer is more prevalent among African American men, the research team is currently pursuing further analyses in more racially diverse populations.
For more on this research, see New Urine-Based Test Detects High-Grade Prostate Cancer.
Reference: "Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer" by Jeffrey J. Tosoian, Yuping Zhang, Lanbo Xiao, Cassie Xie, Nathan L. Samora, Yashar S. Niknafs, Zoey Chopra, Javed Siddiqui, Heng Zheng, Grace Herron, Neil Vaishampayan, Hunter S. Robinson, Kumaran Arivoli, Bruce J. Trock, Ashley E. Ross, Todd M. Morgan, Ganesh S. Palapattu, Simpa S. Salami, Lakshmi P. Kunju, Scott A. Tomlins, Lori J. Sokoll, Daniel W. Chan, Sudhir Srivastava, Ziding Feng, Martin G. Sanda, Yingye Zheng, John T. Wei, Arul M. Chinnaiyan, EDRN-PCA3 Study Group, Ian M. Thompson, Mohamed Bidair, Adam Kibel, Daniel W. Lin, Yair Lotan, Alan Partin, Samir Taneja, David H. Howard, Meredith M. Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H. Patil, Douglas S. Scherr, Jacob Kagan, Jing Fan, Aron Y. Joon, Leonidas E. Bantis and Mark A. Rubin, 18 April 2024, JAMA Oncology.
DOI: 10.1001/jamaoncol.2024.0455
Tosoian is co-first author with Yuping Zhang, PhD, and Lanbo Xiao, PhD, professors at the University of Michigan, where Tosoian and Arul Chinnaiyan, MD, PhD, initiated the study. Chinnaiyan and John T. Wei, MD, are the study's senior authors. Other Vanderbilt researchers who contributed to the study are Nathan Samora, MD, and Hunter Robinson, MD.
The study received funding support from the Prostate Cancer Foundation Young Investigator Award (Tosoian), Michigan-Vanderbilt EDRN Biomarker Characterization Center (U2C CA271854), and the EDRN DMCC (U24 CA086368).
News
Healthcare Headlines: Challenges and Advances in 2026
Health-related updates reveal financial adjustments by Universal Health Services due to Medicaid reimbursement uncertainties, significant pollution-linked health concerns from French-British oil firm Perenco in Congo, drug trial setbacks, potential restructuring at major medical firms, [...]
Scientists Discover the Brain Protein That Helps Alzheimer’s Spread Through the Brain
Scientists have identified a brain protein that may help Alzheimer’s spread, revealing a potential new target for slowing the disease’s progression. Alzheimer’s disease is closely linked to the accumulation of a toxic form of the protein [...]
How Immune Dysregulation Contributes to Psychiatric Disorders
Introduction Growing evidence suggests that disruptions in immune function may play an important role in the development and progression of psychiatric disorders. However, immune mechanisms probably contribute more strongly in some patients than others, [...]
Electrostatic Discharge Boosts Triboelectric Nanogenerator Current and Enables DC Output
Controlled electrical discharges could enable triboelectric nanogenerators to achieve higher peak currents, extending nano-enabled energy harvesting into chemical processing and self-powered sensing. Paper: Electrostatic discharge as a breakthrough strategy for triboelectric nanogenerators. A new review [...]
Swiss laboratory uses old drugs against rare diseases
Researchers at the University of Geneva are combing through collections of approved drugs to find new therapies for rare diseases – with some success. This approach is gaining traction around the world, while pharmaceutical [...]
Nanozyme Aptasensors Show Promise for Faster Food, Health, and Environmental Testing
By pairing robust artificial enzymes with highly selective aptamers, nanozyme aptasensors could help detect disease biomarkers, pathogens, and contaminants faster, but the review shows that real-world deployment still depends on overcoming matrix interference, biofouling, [...]
Paralyzed Man Feels Sensation Again With Brain Stimulation Device
Aneuroprosthetic system has allowed a man with paralysis to grasp and lift objects and feel touch again. The device helped 42-year-old Keith Thomas of Massapequa, New York, who was paralyzed from the chest down [...]
Global Cancer Cases Could Surge 67% by 2050, New Report Warns
New data reveal major geographic disparities and highlight the urgent need for global action on prevention, early detection, and equitable access to treatment. For roughly one in five people worldwide, cancer will become part [...]
A Deadly Ebola-Like Virus Is Spreading. Are We Ready?
BU virologist Nancy Sullivan says the Bundibugyo outbreak in the Democratic Republic of the Congo underscores the need for broader outbreak preparedness. The death of a nurse marked the moment health officials recognized that [...]
Why Most Animal Viruses Never Become Human Pandemics
From receptor mismatch to risky human-animal interfaces, this article explains why spillover is common but true pandemic emergence remains rare. Introduction Humans are constantly exposed to animal viruses through farming, wildlife contact, and the [...]
Stem cell organoids repair heart microvessels in coronary artery disease models
A Stanford University team has shown that vascular organoids derived from human stem cells can repair the heart’s microvessel network in pigs with ischaemic heart disease – a proof-of-concept advancement that could open new therapeutic [...]
Goodbye GP waiting rooms, hello prevention at home
Prevention is suddenly everywhere in NHS reform. The recent £340m community pharmacy deal is moving more services onto the high street. Community Diagnostic Centres are being expanded, and the Neighbourhood Health Framework sets out [...]
Ebola control is weakened by mistrust and cultural insensitivity
Effective response depends on cooperation with communities and frontline workers, writes Zaeem ul Haq The current Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda is exposing dangerous gaps in [...]
Building the Brain Requires Millions of Dangerous DNA Breaks
Scientists discovered that building a healthy brain involves an unexpected step: young neurons routinely break and rapidly repair their own DNA. As the brain develops, newly formed nerve cells must travel through tightly packed tissue [...]
One Tiny Change May Explain How Viruses Jump From Bats to Humans
Scientists found that one tiny genetic change may determine whether a bat virus stays in bats or becomes a human threat. Most infectious disease outbreaks begin when a virus or other pathogen crosses from animals into [...]
Scientists Discover 250+ Genes That Could Lead to New Ways To Prevent Melanoma
The world’s largest study of mole genetics identified hundreds of genes tied to melanoma risk, uncovering potential new drug targets and paving the way for more accurate melanoma screening and prevention. Researchers at QIMR [...]
